Lead Product(s) : Esreboxetine Succinate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Axsome Therapeutics to Submit NDA to US FDA for AXS-14 for Management of Fibromyalgia
Details : AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Submission anticipated in 4Q 2022. Acceptance of the NDA will be subject to the FDA’s review of th...
Brand Name : AXS-14
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2021
Lead Product(s) : Esreboxetine Succinate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?